American College of Gastroenterology

Experts recommend closer follow-up after the surgical removal of pancreatic cysts.

Benjamin Noor, MD, discusses a recent study from ACG that demonstrated that EBTs are associated with improved parameters for weight loss and diabetes.

Tunneled catheters resulted in lower rates of deep vein thrombosis when compared to PICCs.

The findings also showed that large bedded hospitals trended towards higher clostridium difficile infection incidence and mortality rates.

Over the course of the 19 year review, biologic use has increased, while the prevalence of colectomies has decreased.

A new study demonstrates that vedolizumab is associated with real-world corticosteroid-free response and remission in patients with ulcerative colitis and Crohn’s disease.

In a study presented at ACG, investigators find the rate of confirmed HCV infections remained stable pre- and post-interventions.

Brooks Cash, MD, discusses the importance of bowel preparation and surveillance in patients with diabetes.

Anti-TNFs, vedolizumab, ustekinumab, thiopurines, and 5-ASA were all linked to a lower risk of myocardial infarctions.

A poster presented at ACG provides an updated analysis of clostridium difficile infection in the tofacitinib UC clinical program.

Sulindac and eflornithine could help delay the need for lower gastrointestinal surgery for FAP patients.

New data presented at ACG 2020 shows NER1006 bowel preparation to be safe and efficacious in patients with diabetes preparing for their colonoscopy.

Researchers test 3 different doses of mirikizumab in both biologic experienced and naïve Crohn’s disease patients.

An expert discusses a study assessing the effects of low compliance to eosinophilic esophagitis therapies among pediatric patients.

Ustekinumab resulted in a reduction of both stool frequency and rectal bleeding for ulcerative colitis patients.

New research shows patients with chronic liver disease admitted for influenza had an increased risk of disease severity but not a higher odds of mortality.

More than half of the patient population achieved a defined response at both day 14 and week 6.

Research shows dupilumab remains effective in EoE for up to 2 years.

A new study presented at ACG shows vedolizumab to be superior to adalimumab in maintaining early disease control in patients with moderate-to-severe ulcerative colitis.

In data presented at ACG, investigators found a link between sex, lower BMI, and the development of irritable bowel syndrome in patients following a c. diff infection.

In a poster presented during ACG, investigators show data from a long-term extension of the UNIFI trial.

Patients with chronic pancreatitis can exhibit dependence on chronic opioid therapy prior to receiving total pancreatectomy with islet autotransplantation.

Isolation as a result of suspected C. Diff can take a significant financial toll on the healthcare system, thus it is necessary to determine appropriate factors that can predict CDI.

Millie Long, MD, MPH, FACG, associate professor of medicine at the University of North Carolina, Chapel Hill, discusses the exciting research she saw at ACG 2019.

Miguel Regueiro, MD and George Khoudari, MD, both of the Cleveland Clinic, discuss predictors of colectomies for IBD-patients.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Cash talks ACG 2019 highlights and shares the findings of a poster presentation on a new bowel preparation for colonoscopy.

During the ACG meeting, investigators tested a subcutaneous form of vedolizumab to treat ulcerative colitis.

Miguel Regueiro, MD, of the Cleveland Clinic, talks about some of the medications that treat ulcerative colitis and Crohn's disease at the annual ACG meeting.

With the recent FDA approval, ustekinumab could be the first choice to treat ulcerative colitis.